Aspirin/hydrochlorothiazide/enalapril/atorvastatin - Alborz-Darou PharmaceuticalAlternative Names: PolyIran 1; PolyPill 4-1
Latest Information Update: 25 Nov 2015
At a glance
- Originator Alborz Darou
- Developer Alborz Darou; Golestan University of Medical Sciences; Tehran University of Medical Sciences; University of Birmingham
- Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Cardiovascular therapies; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
- Mechanism of Action ACE inhibitors; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Cardiovascular disorders